MeiraGTx’s Phase II Gene Therapy For Parkinson’s Shows Efficacy, Safety

 
• By Joseph Haas
  
MeiraGTx has high hopes for its Parkinson's disease gene therapy candidate (Shutterstock)

More from Neurological

More from R&D